GFF’s Brain Tumor Initiative (BTI) focuses on identifying and developing therapeutic strategies to effectively treat neurofibromatosis type 1 (NF1)-associated transformed gliomas. Gliomas are the most common primary central nervous system (CNS) tumors in NF1 patients, usually involving optic pathways in children. While most of NF1 gliomas are pilocytic astrocytomas, NF1 patients may also develop higher grade tumors, WHO Grade II-IV, that harbor additional mutational abnormalities. In each case, it is often unknown whether the NF1 high-grade glioma is sporadic or transformed from a previously existing low-grade glioma.
BTI aims to conduct studies to provide critical characterization of NF1 transformed glioma and identify the most promising treatments for patients available today. The data and insight generated will inform the development of new targeted therapies in the long term. BTI will be launched in Q2 2022. More details to come!